



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Lenalidomide Maintenance for Multiple Myeloma Drug Update: BCG and Mitomycin Shortage
- **BCCA Website** – New Website Platform
- **BCCA Cancer Drug Manual** – Revised: Paclitaxel, Pembrolizumab Acknowledgement: Editorial Board, Expert Reviewers
- **Benefit Drug List** – New: Lenalidomide (UMYLENMTN) Revised: Pemetrexed (LUAVPP)
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UMYLENMTN Revised: UCNBEV, CNMODPCV, GOOVCATX, GOOVDDCAT, GUNAJPG, UGUPRAD, ULKATOATRA, ULKATOP, LUAVPEM, LUAVPP
- **Errata**
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective 1 January 2015:

Lenalidomide Maintenance for Multiple Myeloma (UMYLENMTN) – This new program has been introduced for patients with multiple myeloma who have achieved stable disease or better response after stem cell transplant. In three phase III trials, maintenance lenalidomide post-transplant was associated with consistently increased progression free survival (42 vs 22 mos; 46 vs 27 mos; 41 vs 23 mos) [*Palumbo. NEJM 2014;371:895, McCarthy. NEJM 2012;366:1770, Attal. NEJM 2012;366:1782*] and one trial was associated with improved overall survival (3-year survival 88% vs 80%, HR 0.62) [*McCarthy. NEJM 2012;366:1770*]. The maintenance dose for lenalidomide is 10 mg daily continuously, a lower dose than can be used for active treatment (e.g., UMYLENDEX). A BCCA Compassionate Access Program application is required for each patient.

DRUG UPDATE

Shortage of Mitomycin and Bacillus Calmette-Guerin (BCG) – The ongoing national shortage of the BCG vaccine (see October issue of Systemic Therapy Update) has led to a temporary shortage of mitomycin (Teva), an alternative intravesical agent for bladder cancer. Mitomycin is also used in chemoradiotherapy for anal cancer. The shortage of mitomycin is expected to last until March 2015. Therefore, the BCCA Systemic Therapy Program recommends the following:

Bladder Cancer:

The BC Cancer Agency, along with HSSBC, has worked closely with Merck to ensure that BCG supplies

EDITOR'S CHOICE

continue to be available. An allocation of BCG was made available on the week of 8 December 2014. Another supply is expected to be available on the week of 19 January 2015. Based on this information and the weekly counts of BCG in all health authorities, BCG supplies should be reasonably maintained. Therefore, BCG should be preferentially used where possible and any remaining mitomycin supplies be conserved for electromotive mitomycin (if equipment available) and patients intolerant to BCG.

Epirubicin, gemcitabine and docetaxel may be considered as alternative intravesical agents if neither BCG nor mitomycin is available. They will be reimbursed by BCCA for this indication during the BCG and mitomycin shortage.

<i>Preference</i>	<i>Intravesical agents</i>	<i>Dose*</i>	<i>Protocol code</i>
1.	Epirubicin ¹	<i>Single post-op dose:</i> 50 mg in 50 mL NS <i>Induction:</i> 50 mg in 50 mL NS weekly x 6 weeks <i>Maintenance:</i> 50 mg in 50 mL NS monthly x 10 months	<i>GUNOS</i>
2.	Gemcitabine ^{2,3}	<i>Induction:</i> 2000 mg in 50 mL NS weekly x 6 weeks <i>Maintenance:</i> 2000 mg in 50 mL NS monthly x 10 months	<i>GUNOS</i>
3.	Docetaxel ⁴	<i>Induction:</i> 75 mg in 100 mL NS weekly x 6 weeks <i>Maintenance:</i> 75 mg in 100 mL NS monthly x 10 months	<i>GUNOS</i>

* intravesically via a catheter with a dwell time of 1-2 hours with the patient changing positions every 15 minutes

Anal Cancer:

Mitomycin is used with concurrent radiotherapy in two combined modality protocols with curative intent (GIFUART, GICART). If mitomycin is not available, two cisplatin containing protocols can be substituted (GIFUPART, GICPART).

References:

1. van der Meijden APM, et al. Intravesical instillation of epirubicin, BCG and BCG plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder. J Urol 2001;166:476.
2. Jones G, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012;1:009294.
3. Addeo R, et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer. J Clin Oncol 2010;28:543.
4. Barlow LJ, et al. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous BCG therapy. J Urol 2013;189:834.

BCCA WEBSITE

New Website Platform – As part of a larger initiative of the Provincial Health Services Authority, the BCCA will be getting a new website based on the Sharepoint 2013 platform. The migration of the contents is currently underway and the tentative launch date is late February 2015.

CANCER DRUG MANUAL

REVISED MONOGRAPHS, PATIENT HANDOUTS AND HAZARDOUS DRUG LIST

The Cancer Drug Manual staff would like to acknowledge the contributions of the Editorial Board as well as our expert reviewers for their ongoing support of the Manual and for generously sharing their time and expertise throughout the year.

Editorial Board

Oncologists

Angela Chan (BCCA)
Jeff Davis (BC Children's Hospital)
Dave Fenton (BCCA)
Deepa Wadhwa (BCCA)

Nurses

Sylvi Baillie (BCCA)
Karen Janes (BCCA)
Fran Topp (BCCA)

Pharmacists

Mandeep Bains (BCCA)
Clarissa Cheng (Burnaby Hospital)
Roberta Esau (BC Children's Hospital)
Sanna Pellatt (BCCA)

Expert Reviewers

Oncologists and Hematologists

Vanessa Bernstein (BCCA)
Winson Cheung (BCCA)
Christian Kollmannsberger (BCCA)
Christopher Lee (BCCA)
John Paul McGhie (BCCA)
Barb Melosky (BCCA)
Sujaatha Narayanan (Leukemia/BMT Program of BC)
Laurie Sehn (BCCA)
Kevin Song (Leukemia/BMT Program of BC)
Kerry Savage (BCCA)

Pharmacists

Alysha Bharmal (BCCA)
Nancy Coady (BCCA)
Linda Hamata (BCCA)
Kimberly Kuik (BCCA)
Juliana Man (BCCA)
Lynne Nakashima (BCCA)
Rose-Marie Reddy (BCCA)
Robert Tillman (BCCA)

REVISED MONOGRAPHS, PATIENT HANDOUTS AND HAZARDOUS DRUG LIST

The following were posted in November 2014 but missed the announcement in the previous Systemic Therapy Update:

- *Supply and Storage, Chemotherapy Preparation Chart* – addition of Accord brand of paclitaxel

Pembrolizumab Interim Monograph and Chemotherapy Preparation Chart:

- *Name* – the name has been changed from Lambrolizumab to Pembrolizumab to match the generic drug name marketed in the US.

Note: Pembrolizumab is not a BCCA Benefit Drug and supply is only available through Health Canada Special Access Programme.

BENEFIT DRUG LIST

NEW PROGRAMS

The following program has been added to the [Benefit Drug List](#) effective 1 January 2015:

Protocol Title	Protocol Code	Benefit Status
Maintenance therapy of multiple myeloma using <i>lenalidomide</i>	UMYLENMTN	Restricted

BENEFIT DRUG LIST

The following program has been revised on the [Benefit Drug List](#) effective 1 January 2015:

Protocol Title	Protocol Code	Benefit Status
First-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed	LUAVPP	Class II (Previously Restricted)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UMYLENMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Maintenance Therapy of Multiple Myeloma Using Lenalidomide

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UCNBEV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
CNMODPCV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modification for renal function clarified</i>	Modified PCV Chemotherapy Of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vinCRiStine
GOOVCATX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Page number corrected, contact physician updated</i>	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Using CARBOplatin and PACLitaxel
GOOVDDCAT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using CARBOplatin and Weekly PACLitaxel
GUNAJPG	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Page number added</i>	Neo-Adjuvant Therapy for Urothelial Carcinoma Using CISplatin and Gemcitabine
UGUPRAD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Therapy for Metastatic Castration Resistant Prostate Cancer Using Radium-223
ULKATOATRA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Information on disease monitoring added</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin
ULKATOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Information on disease monitoring added</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin and DAUNOrubicin

REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LUAVPEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Exclusion updated</i>	Second-Line Treatment of Advanced Non-Small Cell Lung Cancer With Pemetrexed
LUAVPP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement replaced by Class II Benefit status, protocol code revised</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed

ERRATA

DECEMBER 2014

Editor’s Choice, New Programs – the new protocol for glioblastoma multiforme should have been CNTEM60 (not CNTEMM).

Highlights of Changes in Protocols

- The new weekly paclitaxel protocol for breast cancer should have been BRAVTW (not BRAVPW).
- The sentence “It has a slightly higher dose at 90 mg/m² and is given **every** 3 weeks out of 4 weeks, thus” should have been “.....is given weekly for **3 weeks** out of 4 weeks....”.

SEPTEMBER 2014

Editor’s Choice, Dose-Banding of Infusional Fluorouracil – the protocol affected should have been GIRAJFFOX (not GIRAJFFX).

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
CON Pharmacy Educators	www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN
 Rob Watt, BSc (Pharm)